Scleroderma Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Scleroderma Therapeutics Landscape

The global scleroderma therapeutics market is positioned for a profitable growth curve during the forecast period. Key market players in the sector are investing in clinical trials for new therapeutics for scleroderma treatment, and in acquisitions to improve distribution channels in emerging markets.

Here are some key players in the market:

Sanofi
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Novartis AG
Certa Therapeutics
Pfizer Inc.
Teva Pharmaceuticals
Boehringer Ingelheim International
Bristol-Myers Squibb Company
Biogen
F. Hoffman La-Roche Ltd.
Bayer AG
Galderma Laboratories
Aisa Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Scleroderma Therapeutics Market Size, Growth Forecasts 2037

In the News

In March 2024, Cabalette Bio announced FDA granted orphan drug designation to CABA-201 for the treatment of scleroderma. CABA-201 consists fully human CD19-CAR T cell investigational therapy for the treatment of the disease.
In February 2024, Certa Therapeutics FT011 was granted U.S. FDA fast track for the treatment of scleroderma or systemic sclerosis. The fast-track designation was granted based on results of the Phase 2 study that highlighted treatment of scleroderma patients with FT011 for 12 weeks resulted in clinically meaningful improvement in 60% of patients treated with FT011 400mg and 20% of patients in the FT011 200 mg group.

Frequently Asked Questions (FAQ)

The global scleroderma therapeutics sector registered a valuation of USD 2.6 billion in 2024 and is poised to expand at a CAGR of 6.9% during the forecast period, i.e., 2025-2037.

The global scleroderma therapeutics market registered a profitable valuation of USD 2.6 billion in 2024 and is poised to reach USD 6.3 billion by the end of 2037, expanding at a CAGR of 6.9% during the forecast period, i.e., 2025-2037.

The major players in the market are Sanofi, Novartis AG, Certa Therapeutics, Pfizer Inc., Teva Pharmaceuticals, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Biogen, F. Hoffman La-Roche Ltd., Bayer AG, Galderma Laboratories, Aisa Pharmaceuticals, and others.

The oral segment via route of administration in the global scleroderma registered the largest revenue share of 69.8% in 2024. The segment’s growth is attributed to the increasing adoption of treatment due to convenience.

North America is projected to register the largest revenue share of 44.6% by the end of 2037 due to rising investments in research for autoimmune disease to advance curative therapeutics.

Scleroderma Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Scleroderma Therapeutics Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the scleroderma therapeutics market?

What is the outlook for the scleroderma therapeutics market?

Who are the major players dominating the scleroderma therapeutics market?

Which product segment will capture the significant market share for the scleroderma therapeutics sector by 2037?

Which region will provide more business opportunities for the growth of the scleroderma therapeutics market in the future?